BioSpace News Archive

Support Now Available to Assist with Copayments and Premiums

Spherix Incorporated (Nasdaq: SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA).

Indivior PLC today announced that in light of the recent decision by the Court of Appeals for the Federal Circuit (CAFC) vacating the preliminary injunction against Dr. Reddy’s Laboratories (DRL) the Company will host a conference call on December 18th to discuss its strategy and contingency plans.

Newly Renamed as Pinelands Recovery Center, the South N. J. Facility Offers Evidence-Based, Residential Treatment of Adult Drug and Alcohol Addiction

Coverage policy issued by AmeriHealth Caritas

Frazier Healthcare Partners announced Mimi Hancock, Ph.D. has joined its Life Sciences team as a Senior Advisor to assist with attracting top talent for Frazier companies.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases, “Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy”.

Digicom Electronics, Inc., a technology and quality driven electronics manufacturing services company, announces that it has upgraded its Medical Quality Device Certification to ISO 13485:2016

The VENTANA pan-TRK (EPR17341) Assay[1] is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types

Marker Therapeutics, Inc. today announced the appointment of Anthony H. Kim as its new Chief Financial Officer. Michael J. Loiacono, who has served as the Company’s Chief Financial Officer and Chief Accounting Officer since August 2016, will continue in his role as Marker’s Chief Accounting Officer.